Production (Stage)
Esperion Therapeutics, Inc.
ESPR
$1.17
-$0.03-2.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 65.00M | 69.11M | 51.63M | 73.83M | 137.74M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 65.00M | 69.11M | 51.63M | 73.83M | 137.74M |
| Cost of Revenue | 44.10M | 36.61M | 27.68M | 27.07M | 23.48M |
| Gross Profit | 20.90M | 32.51M | 23.95M | 46.76M | 114.26M |
| SG&A Expenses | 43.00M | 36.93M | 39.98M | 44.19M | 41.99M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 87.09M | 73.53M | 67.66M | 71.26M | 65.47M |
| Operating Income | -22.10M | -4.42M | -16.03M | 2.58M | 72.27M |
| Income Before Tax | -40.46M | -21.32M | -29.52M | -61.93M | 61.02M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.46M | -21.32M | -29.52M | -61.93M | 61.02M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.46M | -21.32M | -29.52M | -61.93M | 61.02M |
| EBIT | -22.10M | -4.42M | -16.03M | 2.58M | 72.27M |
| EBITDA | -22.07M | -4.39M | -16.00M | 2.58M | 72.31M |
| EPS Basic | -0.21 | -0.11 | -0.15 | -0.33 | 0.36 |
| Normalized Basic EPS | -0.13 | -0.06 | -0.09 | -0.03 | 0.23 |
| EPS Diluted | -0.21 | -0.11 | -0.15 | -0.33 | 0.34 |
| Normalized Diluted EPS | -0.13 | -0.06 | -0.09 | -0.03 | 0.20 |
| Average Basic Shares Outstanding | 196.13M | 195.57M | 194.93M | 188.79M | 169.26M |
| Average Diluted Shares Outstanding | 196.13M | 195.57M | 194.93M | 188.79M | 189.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |